LRG Science

Home/LRG Science

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2019-12-13T10:07:51-05:00December 13th, 2019|Drug Treatment, Gleevec, LRG Science, News|

Treatment Responses in SDH-deficient GIST – LRG Science

The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2019-12-13T09:39:06-05:00August 13th, 2019|LRG Science, News, SDH-Deficient GIST|

The Life Raft Group Research Model – LRG Science

PDF is available of LRG Science to print here. Real World Evidence in Action Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges [...]

By |2019-05-05T14:20:27-04:00February 21st, 2019|LRG Science, News, Newsletter, Research|